Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo

Biochemical and Biophysical Research Communications

Volumn 302, Issue 4, 2003, Pages 892-897

  Miyata, Yasuyoshi ^a   Ashida, Shingo ^b   Nakamura, Takao ^a   Mochizuki, Yasushi ^a   Koga, Shigehiko ^a   Kanetake, Hiroshi ^a   Shuin, Taro ^b   Kanda, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Angiogenesis; Hepatocyte growth factor; Overexpression; PI 3 kinase; Receptor tyrosine kinase; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; HEPATOCYTE GROWTH FACTOR RECEPTOR KINASE; ISOPROTEIN; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; ENZYME ACTIVITY; EXPRESSION VECTOR; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CARCINOMA; MICROVASCULATURE; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR GENE; TUMOR VASCULARIZATION;

EID: 0345701305     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00281-X     Document Type: Article

References (39)

1. Birchmeier C., Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trend. Cell Biol. 8:1998;404-410.
2. Matsumoto K., Nakamura T. Hepatocyte growth factor: molecular structure, roles in liver regeneration, and other biological functions. Crit. Rev. Oncog. 3:1992;27-54.
3. Rubin J.S., Bottaro D.P., Aaronson S.A. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim. Biophys. Acta. 1155:1993;357-371.
4. Comoglio P.M., Boccaccio C., The C. HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells. 1:1996;347-354.
5. Furge K.A., Zhang Y., Vande Woude G.F. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 19:2000;5582-5589.
6. Schmidt L., Duh F.M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaran A., Bergerheim U.R., Feltis J.T., Casadevall C., Zamarron A., Bernues M., Richard S., Lips C.M.J., Walther M.M., Tsui L.-C., Geil L., Orcutt M.L., Stackhouse T., Lipan J., Slife L., Brauch H., Decker J., Niehans G., Hughson M.D., Moch H., Storkel S., Lerman M.I., Linehan W.M., Zbar B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16:1997;68-73.
7. Schmidt L., Junker K., Nakaigawa N., Kinjerski T., Weirich G., Miller M., Lubensky I., Neumann H.P., Brauch H., Decker J., Vocke C., Brown J.A., Jenkins R., Richard S., Bergerheim U., Gerrard B., Dean M., Linehan W.M., Zbar B. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 18:1999;2343-2350.
8. Park W.S., Dong S., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J., Bae J.H., Hong Y.K., Lee K.S., Lee S.H., Yoo N.J., Jang J.J., Pack S., Zhuang Z., Schmidt L., Zbar B., Lee J.Y. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 59:1999;307-310.
9. Lee J.H., Han S.U., Cho H., Jennings B., Gerrard B., Dean M., Schmidt L., Zbar B., Vande Woude G.F. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 19:2000;4947-4953.
10. Jeffers M., Schmidt L., Nakaigawa N., Webb C.P., Weirich G., Kishida T., Zbar B., Vande Woude G.F. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA. 94:1997;11445-11450.
11. Kuniyasu H., Yasui W., Kitadai Y., Yokozaki H., Ito H., Tahara E. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem. Biophys. Res. Commun. 189:1992;227-232.
12. Liu C., Park M., Tsao M.S. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene. 7:1992;181-185.
13. Di Renzo M.F., Olivero M., Katsaros D., Crepaldi T., Gaglia P., Zola P., Sismondi P., Comoglio P.M. Overexpression of the Met/HGF receptor in ovarian cancer. Int. J. Cancer. 58:1994;658-662.
14. Di Renzo M.F., Poulsom R., Olivero M., Comoglio P.M., Lemoine N.R. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res. 55:1995;1129-1138.
15. Qian C.N., Guo X., Cao B., Kort E.J., Lee C.C., Chen J., Wang L.M., Mai W.Y., Min H.Q., Hong M.H., Vande Woude G.F., Resau J.H., Teh B.T. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 62:2002;589-596.
16. Bergstrom J.D., Hermansson A., Diaz de Stahl T., Heldin N.E. Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture. Br. J. Cancer. 80:1999;650-656.
17. Morello S., Olivero M., Aimetti M., Bernardi M., Berrone S., Di Renzo M.F., Giordano S. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas. J. Cell. Physiol. 189:2001;285-290.
18. Nakamura T., Kanda S., Yamamoto K., Kohno T., Maeda K., Matsuyama T., Kanetake H. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation. Oncogene. 20:2001;7610-7623.
19. Ashida S., Okuda H., Chikazawa M., Tanimura M., Sugita O., Yamamoto Y., Nakamura S., Moriyama M., Shuin T. Detection of circulating cancer cells with von Hippel-Lindau gene mutation in periferal blood of patients with renal cell carcinoma. Clin. Cancer Res. 6:2000;3817-3822.
20. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
21. Y. Miyata, S. Koga, K. Takehara, H. Kanetake, S. Kanda, Expression of the thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues associates with decrease in tumor growth and angiogenesis, Clin. Cancer Res. (2003), in press.
22. Zhang M., Volpert O., Shi Y.H., Bouck N. Maspin is an angiogenesis inhibitor. Nat. Med. 6:2000;196-199.
23. 2 sensing. Science. 292:2001;464-468.
24. 2-regulated prolyl hydroxylation. Science. 292:2001;468-472.
25. Shuin T., Kondo K., Torigoe S., Kishida T., Kubota Y., Hosaka M., Nagashima Y., Kitamura H., Latif F., Zbar B. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54:1994;2852-2855.
26. Besson A., Robbins S.M., Yong V.W. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur. J. Biochem. 263:1999;605-611.
27. Vazquez F., Sellers W.R. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim. Biophys. Acta. 1470:2000;M21-M35.
28. Alimov A., Li C., Gizatullin R., Fredriksson V., Sundelin B., Klein G., Zabarovsky E., Bergerheim U. Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res. 19:1999;3841-3846.
29. Kondo K., Yao M., Kobayashi K., Ota S., Yoshida M., Kaneko S., Baba M., Sasaki N., Kishida T., Kawakami S., Uemura H., Nagashima Y., Nakatani Y., Hosaka M. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int. J. Cancer. 91:2001;219-224.
30. Kohn E.C., Liotta L.A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 55:1995;1856-1862.
31. Fidler I.J. Angiogenesis and cancer metastasis. Cancer J. Sci. Am. 6(Suppl. 2):2000;S134-S141.
32. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
33. Dong G., Chen Z., Li Z.Y., Yeh N.T., Bancroft C.C., Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 61:2001;5911-5918.
34. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21:2001;3995-4004.
35. Stiehl D.P., Jelkmann W., Wenger R.H., Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor 1α by insulin and interleukin-1β involves the phosphatidylinositol 3-kinase pathway. FEBS Lett. 512:2002;157-162.
36. Jones A., Fujiyama C., Blanche C., Moore J.W., Fuggle S., Cranston D., Bicknell R., Harris A. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 α and hypoxia-inducible factor-2 α in human bladder tumors and cell lines. Clin. Cancer Res. 7:2001;1263-1272.
37. Antonyak M.A., Moscatello D.K., Wong A.J. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem. 273:1998;2817-2822.
38. Inoue G., Cheatham B., Kahn C.R. Different pathways of postreceptor desensitization following chronic insulin treatment and in cells overexpressing constitutively active insulin receptors. J. Biol. Chem. 271:1996;28206-28211.
39. Moscatello D.K., Holgado-Madruga M., Emlet D.R., Montgomery R.B., Wong A.J. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. 273:1998;200-206.